Biotinylated Cynomolgus CD20 / MS4A1 Full Length Protein, His,Avitag™ (Nanodisc)

ユーザーレビュー
製品番号/仕様
価格
数量
CD0-C82E4-20ug
$1020.00
CD0-C82E4-100ug
$1820.00
ETA of in-stock products:2 business days
総アイテム数 製品金額$ 0

製品詳細

  • Application

    1. Cell based assay (FACS or functional assay)
    2. Affinity testing (SPR / BLI)
    3. Screening (ELISA)
  • Synonyms

    MS4A1, CD20, MS4A-1

  • Source

    Nanodisc Biotinylated Cynomolgus CD20 Full Length Protein, His,Avitag (CD0-C82E4) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # M4ZHZ6-1 ).

    Predicted N-terminus: Met 1

    Request for sequence

  • Molecular Characterization

    CD20 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 36.9 kDa. The protein migrates as 24-25 kDa and 40-41 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

    *The isotype control of empty/mock nanodisc (Cat. No. APO-H81Q5) is sold separately and not included in protein, you can follow the link for product information.

    1. Structure

      Nanodisc membrane protein is wrapped by a synthetic phospholipid bilayer membrane structure, composed of membrane scaffold proteins (MSPs) and phospholipids.

    2. Synthesis Process

      Nanodisc reconstitution is a self-assembly process that starts from purified, detergent-solubilized membrane proteins and reconstitutes them into synthetic phospholipid bilayers stabilized by MSP1D1 membrane scaffold protein. This creates a stable, detergent-free environment that preserves native conformation and biological activity, with excellent homogeneity and full compatibility with cell-based assays such as FACS and binding assays in antibody discovery and screening (ELISA),etc.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Protein Ratio

    Passed as determined by the HABA assay / binding ELISA.

  • Purity

    >80% as determined by SDS-PAGE.

  • Formulation

    Supplied as 0.2 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Shipping and Storage

    This product is supplied and shipped on dry ice.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 3 months under sterile conditions.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

お客様はこちらも閲覧

データ表示

  • SDS-PAGE

    CD20 SDS-PAGE

    Biotinylated Cynomolgus CD20 Full Length Protein, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 80% (With Star Ribbon Pre-stained Protein Marker).

  • Bioactivity-ELISA

     CD20 ELISA

    Immobilized Biotinylated Cynomolgus CD20 Full Length Protein, His,Avitag (Cat. No. CD0-C82E4) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Biosimilar Ofatumumab with a linear range of 0.039-0.625 μg/mL (QC tested).

    Protocol
  •  CD20 ELISA

    Immobilized Biotinylated Cynomolgus CD20 Full Length Protein, His,Avitag (Cat. No. CD0-C82E4) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Biosimilar Obinutuzumab with a linear range of 0.04-1 ng/mL (Routinely tested).

    Protocol
  • Bioactivity-SPR

     CD20 SPR

    Rituximab biosimilar (Cat. No. CD0-M36)captured on Protein A Chip can bind Biotinylated Cynomolgus CD20 Full Length Protein, His,Avitag (Cat. No. CD0-C82E4) with an affinity constant of 22 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol

ユーザーレビュー
コメントを投稿

バックグランド

A B-lymphocyte surface antigen expressed from pre-B to mature B cells, but absent on plasma cells. It functions as a calcium channel and is a validated immunotherapy target, famously exploited by rituximab for treating B-cell malignancies and autoimmune disorders.

最新の進展

 
医薬品開発の進捗
  • 英語名:

    B-lymphocyte antigen CD20

  • カテゴリ:

  • 市販の医薬品数:

    35 詳細

  • 治験医薬品数:

    132 詳細

  • 最新の開発ステージ:

    Approved

お問い合わせ
医薬品候補ライセンス
他の関連情報
  • 製品情報
  • 製品詳細
  • お客様はこちらも閲覧
  • データ表示
  • ユーザーレビュー
  • 背景
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8